 Connection
Jorge Saucedo to Ticlopidine
This is a "connection" page, showing publications Jorge Saucedo has written about Ticlopidine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.662 |
|
|
|
-
Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55.
Score: 0.383
-
Saucedo JF, Aude W, Pacheco R, Thorn B, Matin Z, Husain K, Garza L. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study). Am J Cardiol. 2005 Jun 15; 95(12):1453-6.
Score: 0.228
-
Giordana F, Montefusco A, D'Ascenzo F, Moretti C, Scarano S, Abu-Assi E, Raposeiras-Roub?n S, Henriques JP, Saucedo J, Gonz?lez-Juanatey JR, Wilton SB, Kikkert WJ, Nu?ez-Gil I, Ariza-Sole A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Huczek Z, Nie SP, Fujii T, Correia L, Kawashiri MA, Garc?a-Acu?a JM, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, M?llmann H, Shiomi H, Kowara M, Filipiak K, Wang X, Yan Y, Fan JY, Ikari Y, Nakahayshi T, Sakata K, Yamagishi M, Kalpak O, Kedev S, Gaita F. Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe. Int J Cardiol. 2016 Oct 01; 220:488-95.
Score: 0.122
-
Diodati JG, Saucedo JF, Cardillo TE, Jakubowski JA, Henneges C, Effron MB, Lipkin FR, Walker JR, Duvvuru S, Sundseth SS, Fisher HN, Angiolillo DJ. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost. 2014 Aug; 112(2):311-22.
Score: 0.105
-
Braun O?, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thromb Haemost. 2013 Dec; 110(6):1223-31.
Score: 0.101
-
Diercks DB, Kontos MC, Hollander JE, Mumma BE, Holmes DN, Wiviott S, Saucedo JF, de Lemos JA. ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. Am J Emerg Med. 2013 Jul; 31(7):1005-11.
Score: 0.099
-
Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012 Jul; 34(1):44-55.
Score: 0.093
-
Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, W?jcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):347-56.
Score: 0.092
-
Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46.
Score: 0.084
-
Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010 Sep 21; 56(13):1017-23.
Score: 0.082
-
Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, DiChiara J, Antonino MJ, Mahla E, Singla A, Herzog WR, Bassi AK, Hennebry TA, Gesheff TB, Tantry US. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol. 2009 Feb 24; 53(8):648-57.
Score: 0.074
-
Cohen M, Hoekstra J, Giugliano R, Granger CB, Gurbel PA, Hollander JE, Manoukian SV, Pollack CV, Saucedo JF. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. J Interv Cardiol. 2008 Aug; 21(4):283-99.
Score: 0.071
-
Jennings LK, Saucedo JF. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Curr Opin Cardiol. 2008 Jul; 23(4):302-8.
Score: 0.070
-
Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, Roe MT, Bhatt DL, McNamara RL, Alexander KP. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv. 2014 Aug; 7(4):585-93.
Score: 0.027
-
Leonardi S, Chen AY, Gharacholou SM, Wang TY, de Lemos JA, Saucedo JF, Peterson ED, Roe MT. Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. Am Heart J. 2012 Oct; 164(4):502-8.
Score: 0.024
-
Kornowski R, Hong MK, Saucedo J, Satler LF, Pichard AD, Kent KM, Greenberg A, Leon MB. Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes. Am J Cardiol. 1998 Nov 15; 82(10):1163-7.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|